title: Pyruvate prevents restraint-induced immunosuppression via alterations in glucocorticoid responses.
abstract: Stress-evoked immunosuppression may reflect increased demands on cellular energy signaled via elevated glucocorticoid concentrations. We hypothesized that treatment with pyruvate, an alternative energy source, would ameliorate restraint-induced elevation of glucocorticoids and that this reduction in glucocorticoid exposure will prevent stress-induced immunosuppression. We provided exogenous pyruvate to mice exposed to repeated restraint and then assessed splenocyte counts and splenocyte proliferation in response to the mitogen, concanavalin A as well as IgM production in response to keyhole limpet hemocyanin. Immune function was suppressed in mice undergoing repeated restraint but not in mice exposed to repeated restraint followed by pyruvate treatment. All mice exposed to restraint, regardless of pyruvate supplementation, displayed equivalent occurrences of repeated elevations in corticosterone concentrations; however, the cumulative exposure to corticosterone after one episode of restraint was reduced in those mice treated with pyruvate after restraint. Finally, we tested the immunoprotective ability of pyruvate supplementation in the presence of chronically elevated corticosterone. Mice implanted with restraint-like concentrations of corticosterone after adrenalectomy decreased splenocyte counts, compared with either unmanipulated mice or mice that were implanted with a cholesterol pellet after adrenalectomy, regardless of pyruvate supplementation. These data suggest that pyruvate does not possess immunoprotective properties in the presence of chronically elevated corticosterone. Pyruvate supplementation preserves immune function during exposure to repeated restraint stressors; altered dynamics of corticosterone concentrations after pyruvate administration may mediate this immunoprotection. Pyruvate prevents restraint-induced immunosuppression via alterations in the glucocorticoid response to restraint.
authors.affiliation: Townshend Hall, 1885 Neil Avenue Mall, Columbus, Ohio 43210, USA.
authors.forename: Gretchen N
authors.initials: GN
authors.lastname: Neigh
authors.forename: Stephanie L
authors.initials: SL
authors.lastname: Bowers
authors.forename: Leah M
authors.initials: LM
authors.lastname: Pyter
authors.forename: Michelle L
authors.initials: ML
authors.lastname: Gatien
authors.forename: Randy J
authors.initials: RJ
authors.lastname: Nelson
mesh_terms: D000818:Animals; D000917:Antibody Formation / Q000276:immunology; D001835:Body Weight; D002452:Cell Count; D002455:Cell Division / Q000276:immunology; D003345:Corticosterone / Q000097:blood; D003346:Corticotropin-Releasing Hormone / Q000378:metabolism; D005938:Glucocorticoids / Q000276:immunology*; D007108:Immune Tolerance / Q000187:drug effects* / Q000502:physiology*; D007328:Insulin / Q000097:blood; D020738:Leptin / Q000097:blood; D008297:Male; D051379:Mice; D008810:Mice, Inbred C57BL; D010286:Paraventricular Hypothalamic Nucleus / Q000378:metabolism; D019289:Pyruvic Acid / Q000494:pharmacology*; D012149:Restraint, Physical; D015398:Signal Transduction / Q000187:drug effects / Q000276:immunology; D013154:Spleen / Q000166:cytology; D013312:Stress, Physiological / Q000276:immunology*
chemical_list: D005938:Glucocorticoids; D007328:Insulin; D020738:Leptin; D019289:Pyruvic Acid; D003346:Corticotropin-Releasing Hormone; D003345:Corticosterone